CORAT Therapeutics Takes Over the Fast Track Development of a Novel COVID-19 Antibody Drug Program

YUMAB  spin-off CORAT Therapeutics develops SARS-CoV-2 neutralizing antibody therapy

Braunschweig, June 16, 2020 – Today YUMAB announces the first financing round of its spin-off CORAT Therapeutics GmbH to advance the development of COVID-19 antibody drug candidates. Financial investments are provided by the German Federal State of Lower Saxony and a group of private investors from Braunschweig. CORAT Therapeutics will continue the pre-clinical development of the lead antibody drug candidate to potentially begin clinical development by the end of 2020.

Read YUMAB’s press release (English)
Read YUMAB’s press release (German)

Read Media Coverage (English / German)

Contact

YUMAB GmbH
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
Email: info@yumab.com